https://scholars.lib.ntu.edu.tw/handle/123456789/641634
Title: | Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol | Authors: | Schwartz, Gregory G Szarek, Michael Bittner, Vera A Diaz, Rafael Goodman, Shaun G Jukema, J Wouter Landmesser, Ulf López-Jaramillo, Patricio Manvelian, Garen Pordy, Robert Scemama, Michel Sinnaeve, Peter R White, Harvey D Gabriel Steg, Ph JUEY-JEN HWANG |
Keywords: | PCSK9 inhibitor; acute coronary syndrome; lipoprotein(a); low-density lipoprotein cholesterol | Issue Date: | 3-Aug-2021 | Journal Volume: | 78 | Journal Issue: | 5 | Start page/Pages: | 421 | Source: | Journal of the American College of Cardiology | Abstract: | Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk. |
URI: | https://www.scopus.com/record/display.uri?eid=2-s2.0-85110291084&doi=10.1016%2fj.jacc.2021.04.102&origin=inward&txGid=fa0a0f1033879bc6a1a9f1dcd4e0c6a8 https://scholars.lib.ntu.edu.tw/handle/123456789/641634 |
ISSN: | 07351097 | DOI: | 10.1016/j.jacc.2021.04.102 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.